217 related articles for article (PubMed ID: 17575162)
21. Radioimmunotherapy of CD22-expressing Daudi tumors in nude mice with a 90Y-labeled anti-CD22 monoclonal antibody.
Vallera DA; Brechbiel MW; Burns LJ; Panoskaltsis-Mortari A; Dusenbery KE; Clohisy DR; Vitetta ES
Clin Cancer Res; 2005 Nov; 11(21):7920-8. PubMed ID: 16278417
[TBL] [Abstract][Full Text] [Related]
22. Radioimmunotherapy for B-cell non-Hodgkin lymphoma.
Nowakowski GS; Witzig TE
Clin Adv Hematol Oncol; 2006 Mar; 4(3):225-31. PubMed ID: 16728934
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with
Yoon JT; Longtine MS; Marquez-Nostra BV; Wahl RL
J Nucl Med; 2018 Aug; 59(8):1219-1224. PubMed ID: 29348316
[TBL] [Abstract][Full Text] [Related]
24. Applying near-infrared photoimmunotherapy to B-cell lymphoma: comparative evaluation with radioimmunotherapy in tumor xenografts.
Heryanto YD; Hanaoka H; Nakajima T; Yamaguchi A; Tsushima Y
Ann Nucl Med; 2017 Nov; 31(9):669-677. PubMed ID: 28741052
[TBL] [Abstract][Full Text] [Related]
25. Radioimmunotherapy in follicular lymphoma.
Illidge T; Morschhauser F
Best Pract Res Clin Haematol; 2011 Jun; 24(2):279-93. PubMed ID: 21658624
[TBL] [Abstract][Full Text] [Related]
26. Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models.
Frost SH; Frayo SL; Miller BW; Orozco JJ; Booth GC; Hylarides MD; Lin Y; Green DJ; Gopal AK; Pagel JM; Bäck TA; Fisher DR; Press OW
PLoS One; 2015; 10(3):e0120561. PubMed ID: 25785845
[TBL] [Abstract][Full Text] [Related]
27. Alpha radioimmunotherapy using
Cheal SM; McDevitt MR; Santich BH; Patel M; Yang G; Fung EK; Veach DR; Bell M; Ahad A; Vargas DB; Punzalan B; Pillarsetty NVK; Xu H; Guo HF; Monette S; Michel AO; Piersigilli A; Scheinberg DA; Ouerfelli O; Cheung NV; Larson SM
Theranostics; 2020; 10(25):11359-11375. PubMed ID: 33052220
[TBL] [Abstract][Full Text] [Related]
28. Pretargeted radioimmunotherapy for B-cell lymphomas.
Green DJ; Pagel JM; Pantelias A; Hedin N; Lin Y; Wilbur DS; Gopal A; Hamlin DK; Press OW
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5598s-5603s. PubMed ID: 17875795
[TBL] [Abstract][Full Text] [Related]
29. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
[TBL] [Abstract][Full Text] [Related]
30. Therapy of small subcutaneous B-lymphoma xenografts with antibodies conjugated to radionuclides emitting low-energy electrons.
Michel RB; Rosario AV; Andrews PM; Goldenberg DM; Mattes MJ
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):777-86. PubMed ID: 15701868
[TBL] [Abstract][Full Text] [Related]
31. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
Liu C; DeNardo G; Tobin E; DeNardo S
Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
[TBL] [Abstract][Full Text] [Related]
32. Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.
Buchsbaum DJ; Khazaeli MB; Axworthy DB; Schultz J; Chaudhuri TR; Zinn KR; Carpenter M; LoBuglio AF
Clin Cancer Res; 2005 Nov; 11(22):8180-5. PubMed ID: 16299250
[TBL] [Abstract][Full Text] [Related]
33. Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts.
Tuscano JM; O'Donnell RT; Miers LA; Kroger LA; Kukis DL; Lamborn KR; Tedder TF; DeNardo GL
Blood; 2003 May; 101(9):3641-7. PubMed ID: 12511412
[TBL] [Abstract][Full Text] [Related]
34. Advantage of lutetium-177 versus radioiodine immunoconjugate in targeted radionuclide therapy of b-cell tumors.
Repetto-Llamazares A; Abbas N; Bruland ØS; Dahle J; Larsen RH
Anticancer Res; 2014 Jul; 34(7):3263-9. PubMed ID: 24982330
[TBL] [Abstract][Full Text] [Related]
35. Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose.
Förster GJ; Santos EB; Smith-Jones PM; Zanzonico P; Larson SM
J Nucl Med; 2006 Jan; 47(1):140-9. PubMed ID: 16391198
[TBL] [Abstract][Full Text] [Related]
36. Improving the treatment of non-Hodgkin lymphoma with antibody-targeted radionuclides.
Sharkey RM; Karacay H; Goldenberg DM
Cancer; 2010 Feb; 116(4 Suppl):1134-45. PubMed ID: 20127947
[TBL] [Abstract][Full Text] [Related]
37. A bispecific antibody directly induces lymphoma cell death by simultaneously targeting CD20 and HLA-DR.
Zeng J; Liu R; Wang J; Fang Y
J Cancer Res Clin Oncol; 2015 Nov; 141(11):1899-907. PubMed ID: 25773122
[TBL] [Abstract][Full Text] [Related]
38. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody.
Kaminski MS; Zasadny KR; Francis IR; Milik AW; Ross CW; Moon SD; Crawford SM; Burgess JM; Petry NA; Butchko GM
N Engl J Med; 1993 Aug; 329(7):459-65. PubMed ID: 7687326
[TBL] [Abstract][Full Text] [Related]
39. Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma.
Meredith RF; Knox SJ
Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S15-22. PubMed ID: 16979433
[TBL] [Abstract][Full Text] [Related]
40. Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-biotin.
Yao Z; Zhang M; Axworthy DB; Wong KJ; Garmestani K; Park L; Park CW; Mallett RW; Theodore LJ; Yau EK; Waldmann TA; Brechbiel MW; Paik CH; Pastan I; Carrasquillo JA
Cancer Res; 2002 Oct; 62(20):5755-60. PubMed ID: 12384535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
